We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Gene Therapy for Niemann-Pick Type a Diseases Moves Forward
News

Gene Therapy for Niemann-Pick Type a Diseases Moves Forward

Gene Therapy for Niemann-Pick Type a Diseases Moves Forward
News

Gene Therapy for Niemann-Pick Type a Diseases Moves Forward

Credit: Pixabay
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Gene Therapy for Niemann-Pick Type a Diseases Moves Forward"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Research led by Dr. Krystof Bankiewicz, who recently joined The Ohio State University College of Medicine, shows that gene replacement therapy for Niemann-Pick type A disease is safe for use in nonhuman primates and has therapeutic effects in mice.

These research findings are published online in the journal Science Translational Medicine.

Prior to joining Ohio State as a professor of neurosurgery, Bankiewicz conducted this translational gene therapy research at the University of California at San Francisco, in conjunction with researchers in New York, Massachusetts and Spain.

Niemann-Pick disease primarily affects children, has no known cure and is often fatal. It's caused by mutations in a gene that causes a deficiency of a specific enzyme, acid sphingomyelinase (ASM). With this disease, the body's ability to metabolize fat within cells is affected, causing these cells to malfunction and, eventually, die. This inherited disease can affect the brain, nerves, liver, spleen, bone marrow and lungs.

Researchers evaluated the safety and effectiveness of adeno-associated viral vector serotype 9 (AAV9)-based gene therapy. Using a newly developed cerebrospinal fluid delivery method into a specific area of the brain allowed widespread gene expression in the brain and spinal cord of nonhuman primates without signs of toxicity.

In addition, the treatment provided a "bystander effect" by preventing motor and memory impairment and increased survival in a mouse model of the disease, said Bankiewicz, who also is a member of Ohio State's Neurological Institute.

"This is the 'proof of concept' of gene therapy in animal models for this disease. It's a big jump in the development process as we work toward one day being able to safely give this therapy to children who otherwise would die by age 3," Bankiewicz said. "Our plan is to translate this exciting data into human clinical trials at The Ohio State University Wexner Medical Center within the next couple of years.

Based on this research, Bankiewicz and his team, including co-author Lluis Samaranch, an assistant professor of neurological surgery at Ohio State, will move forward with additional animal studies in preparation to eventually begin clinical trials in humans.

"Dr. Bankiewicz is a world leader in neuro-restorative medicine - particularly gene therapy. With his recruitment here - along with the expertise of his five-member research team he's bringing with him - The Ohio State University College of Medicine is making a strong commitment to developing a gene therapy program to develop treatments for this and other diseases, such as Parkinson's and Alzheimer's," said Dr. K. Craig Kent, dean of Ohio State College of Medicine.

Throughout his career, Bankiewicz has maintained a strong focus on the development of translational approaches to drug, gene and cell replacement therapies.

His research has focused on new treatments of serious diseases, including brain cancer, Parkinson's disease, Huntington's disease, Alzheimer's diseases, pediatric neurotransmitter deficiency and lysosomal storage disorders. At Ohio State, Bankiewicz will work closely with the department of neurological surgery to conduct other gene replacement therapy clinical trials in humans.

Reference: Samaranch et al. 2019. Adeno-associated viral vector serotype 9–based gene therapy for Niemann-Pick disease type A. Science Translational Medicine. DOI: 10.1126/scitranslmed.aat3738. 


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement